PVRIG (JS-009 Biosimilar) Recombinant Monoclonal Antibody

This recombinant monoclonal antibody is developed as a research-grade biosimilar to JS-009, targeting PVRIG (poliovirus receptor-related immunoglobulin domain-containing protein), also known as CD112R. PVRIG functions as an immune checkpoint receptor expressed on T cells and NK cells that delivers inhibitory signals upon binding to its ligand PVRL2 (CD112), which is frequently upregulated on tumor cells and antigen-presenting cells. By engaging PVRL2, PVRIG suppresses T cell activation and cytotoxic function, contributing to tumor immune evasion. This inhibitory pathway has emerged as a significant mechanism in cancer immunology, particularly in solid tumors where PVRIG expression correlates with immune exhaustion and poor clinical outcomes.

JS-009 represents a therapeutic antibody designed to block the PVRIG-PVRL2 interaction, thereby restoring anti-tumor immune responses. This biosimilar provides researchers with a valuable tool for investigating PVRIG-mediated immune regulation, exploring combination immunotherapy strategies, and studying checkpoint inhibitor mechanisms in oncology research. It supports investigations into T cell exhaustion, tumor microenvironment dynamics, and novel immunotherapeutic approaches targeting the TIGIT/PVRIG axis.